- Home
- ZTR vs PROK Comparison
ZTR vs PROK Comparison
Compare ZTR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- PROK
- Stock Information
- Founded
- ZTR 1988
- PROK 2015
- Country
- ZTR Australia
- PROK United States
- Employees
- ZTR N/A
- PROK N/A
- Industry
- ZTR Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZTR Finance
- PROK Health Care
- Exchange
- ZTR Nasdaq
- PROK Nasdaq
- Market Cap
- ZTR 350.0M
- PROK 334.8M
- IPO Year
- ZTR N/A
- PROK N/A
- Fundamental
- Price
- ZTR $6.64
- PROK $3.26
- Analyst Decision
- ZTR
- PROK Strong Buy
- Analyst Count
- ZTR 0
- PROK 4
- Target Price
- ZTR N/A
- PROK $6.25
- AVG Volume (30 Days)
- ZTR 219.4K
- PROK 2.8M
- Earning Date
- ZTR 01-01-0001
- PROK 11-11-2025
- Dividend Yield
- ZTR 12.09%
- PROK N/A
- EPS Growth
- ZTR N/A
- PROK N/A
- EPS
- ZTR N/A
- PROK N/A
- Revenue
- ZTR N/A
- PROK $527,000.00
- Revenue This Year
- ZTR N/A
- PROK $427.89
- Revenue Next Year
- ZTR N/A
- PROK N/A
- P/E Ratio
- ZTR N/A
- PROK N/A
- Revenue Growth
- ZTR N/A
- PROK N/A
- 52 Week Low
- ZTR $4.50
- PROK $0.46
- 52 Week High
- ZTR $6.60
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ZTR 81.20
- PROK 54.93
- Support Level
- ZTR $6.22
- PROK $2.34
- Resistance Level
- ZTR $6.31
- PROK $3.02
- Average True Range (ATR)
- ZTR 0.05
- PROK 0.17
- MACD
- ZTR 0.03
- PROK 0.03
- Stochastic Oscillator
- ZTR 99.98
- PROK 65.59
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.